Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Project to Move Engineered Tissue and Organs from Lab to the Bedside, Operating Room

By BiotechDaily International staff writers
Posted on 13 May 2014
Image: Lab-grown vaginal organs implanted in patients (Photo courtesy of the Wake Forest Institute for Regenerative Medicine).
Image: Lab-grown vaginal organs implanted in patients (Photo courtesy of the Wake Forest Institute for Regenerative Medicine).
As developments in lab-created organs and tissues continue to advance, the challenge becomes how to translate the technology from the laboratory to the operating room. Two US universities are now exploring manufacturing platforms to mass produce customized engineered tissues and organs.

Developing a way to scale up personalized lab-created organs and tissues would benefit patients around the world who must wait for donated organs to receive transplants. North Carolina (NC) State University’s (Raleigh, NC, USA) industrial and systems engineering department (NC State ISE) engineers are partnering with biomedical scientists at the Wake Forest Institute for Regenerative Medicine (WFIRM; Winston-Salem, NC, USA). Together, the institutions are creating advancements in 3D technology, computer-aided modeling and intelligent automation to print tissues and organs for patients. With their focus on precision, computer modeling and three-dimensional (3D) printing will help scientists scale up the tissue engineering processes currently being done manually.

The future of organs-on-demand requires the mass generation of precise parts that are specific to each individual recipient. The development entails combining the cells and a scaffold, or a model that forms the essential shape. The support structure is designed to gradually dissolve after implantation in the body. At the same time, the scaffolding material is being absorbed by the body, and the cells lay down materials to form a permanent support structure, progressively replacing the engineered scaffold with a new organ.

Leading corporate and education specialists in medicine, engineering, and science gathered at this year’s Regenerative Medicine Foundation Conference, May 5-7, 2014, held in San Francisco, CA, USA, to share firsthand accounts of their visions and challenges of bio-tissue manufacturing. Dr. Binil Starly, director of NC State ISE’s laboratory for engineering biological tissue systems, uses bioprinting to devise ways for mass producing engineered tissue and also shared data about these latest developments, including a patent-pending process, which is collaboration between WFIRM and NCSU, for providing replacement skin for burn victims.

“It is one thing to be able to grow an organ but another to take that ability to the bedside, so involving manufacturing engineers early on in the biological research phase is vital to achieving commercialization,” said Dr. Starly. “NC State ISE reviews the scientific process for growing tissue cells, and then applies 3D technologies and algorithms to automate it, so a very sensitive biological process can be replicated safely and effectively.”

Dr. Anthony Atala, director of WFIRM and NC State ISE advisory board member, moderated a panel on the marketing of regenerative medicine therapies at the conference. WFIRM scientists have developed lab-grown organs, such as bladders, vaginal organs, and urine tubes successfully used in patients.

Related Links:

North Carolina State University
Wake Forest Institute for Regenerative Medicine 



Channels

Genomics/Proteomics

view channel
Image: The photo shows a mouse pancreatic islet as seen by light microscopy. Beta cells can be recognized by the green insulin staining. Glucagon is labeled in red and the nuclei in blue (Photo courtesy of Wikimedia Commons).

Regenerative Potential Is a Trait of Mature Tissues, Not an Innate Feature of Newly Born Cells

Diabetes researchers have found that the ability of insulin-producing beta cells to replicate and respond to elevated glucose concentrations is absent in very young animals and does not appear until after weaning.... Read more

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.